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Introduction 
Comorbidity or the co-occurrence of mental disorders and substance use disorders is 
common. The prevalence of comorbidity in the community and the complex 
interactions that occur between the two sets of disorders, should raise doubts about 
the manner in which we continue to deal with each entity separately. As clinicians we 
need to consider these problems as part of a whole complex of phenomena that are 
closely linked to one another.  
However there are significant problems with the management of people with 
comorbidity. There is a dearth of evidence about best practice. Specialist mental 
health or alcohol and other drugs services where they are available, are usually 
separated physically administratively and philosophically. Until recently training for 
general practitioners has been inadequate for the problems that we face on a day to 
day basis either in the mental health field or the alcohol and other drugs field.  
This resource has been developed as a result of work that PARC undertook in 2001 
with the development of a set of principles for the management of people with 
comorbidity. These principles are outline at the start of this resource.  
More detailed information about specific aspects of management of the different 
types of co-existing mental disorders and substance use problems then follows. 
 Of course things are never that simple. The information available is patchy and 
much of it is not based on high levels of evidence. In addition many people with co-
morbidity have more than one mental disorder and may have problematic use of 
several drugs. This resource is a simple guide for clinicians to start to work from. 
 
Chris Holmwood 
Primary Mental Health Care  
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Abridged principles of management of people with 
dual diagnosis or comorbidity of mental health 
problems and substance use 
Mental disorders and substance use occur together very frequently and interact 
negatively on one another. Their management requires a long-term perspective. 
Actual GP interventions may be brief or extended over a period of time. A doctor-
patient relationship based on honesty, trust and respect will form the basis for 
effective therapy. Active listening skills and a patient centered clinical method should 
be used to establish rapport, to develop a common understanding of the problems 
and an agreed management plan.  
Detection 
GPs should routinely enquire about substance use.  
When a patient presents with either a substance use related problem or a mental 
disorder then the GP should enquire about the other.  
Comorbidity should be suspected when progress or response to therapy is not 
straightforward.  
Assessment 
A full assessment often takes several consultations.  
This assessment should include determination of: 
• The patterns of drug use  
• the day to day problems associated with the substance use,  
• the reasons for the use and  
• the effect that it might be having on the mental health problem 
• the nature of the mental disorder itself, diagnosis, previous treatments 
and responses.  
General Management 
Management should be based on the patient’s readiness for change. This readiness 
for change might be different for the management of the substance use than it is for 
the mental disorder.  
Management should aim to increase the patient’s awareness of the negative effect 
that the substance use and the mental disorder are having on each other.  
Management should involve family or carers where appropriate. 
Specific management 
Detoxification should be offered as a first step to enable engagement in long-term 
approaches and decision making.  
Specific management steps should include where appropriate: 
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• Information provision 
• Structured problem solving 
• Motivational interviewing 
• Brief behavioural or cognitive approaches. 
Pharmacological approaches 
Clinicians should avoid using drugs of dependence unless as part of a harm 
reduction plan (eg methadone or buprenorphine) 
Benzodiazepines should not be used for more than a few days. Generally longer 
acting benzodiazepines are preferable.  
Clinicians should consider whether the current medication for the mental disorder is 
adequate or causing side-effects as the patient may be self medicating with non 
prescribed drugs to relieve symptoms or side effects. 
The clinician should consider potential interactions between all substances used. 
If there is drug-seeking behaviour then engagement of the patient in a planned and 
limited prescribing program is required. (eg HIC consent for all prescribing 
information to go to the one prescriber)  
Referral 
Consider referral when: 
• Self harm risk or risk to others is present 
• Acute exacerbation of mental disorder occurs 
• Drug dependence with major associated problems (legal, health, social) is 
present. 
• Complicated detox is anticipated.  
It is important for GPs to develop links with local specialist mental health or drug and 
alcohol services (where they exist) 
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The Common Drug Groups 
Cannabis/Hallucinogens 
Cannabis (marijuana, hash, grass, dope), LSD (acid), Psilocybin (Magic Mushrooms) 
Datura (Angel’s trumpet), Anticholinergic drugs, e.g. benztropine, benzhexol, 
orphenadrine.  
In small quantities, users find cannabis both relaxing and stimulating. The senses are 
enhanced and it improves the appetite. The drug is often used in a group as it 
enhances sociability and at low doses it causes a high that includes feelings of 
relaxation and happiness. In larger quantities (or with stronger strains), cannabis may 
produce effects similar to LSD. LSD (Lysergic Acid Diethylamide or acid) is a 
hallucinogenic or psychedelic drug. LSD and large amounts of cannabis can trigger 
underlying mental problems and produce delusions, paranoia and schizophrenia-like 
states. They can also produce extreme anxiety states or panic attacks, not only while 
the person is under the influence of the drug, but for some time after. In this way 
these drugs may produce long standing changes in the personality of the user. 
Anticholinergic drugs, e.g. benztropine, benzhexol, orphenadrine may be prescribed 
to alleviate extrapyramidal symptoms in patients with psychosis. However these 
drugs may themselves lead to hallucinations, and are therefore sometimes sold for 
recreational use. Several psychotropic drugs have less marked anticholinergic 
effects, e.g. tricyclic antidepressants, thioridazine and may interact with prescribed or 
unsanctioned drugs to produce an anticholinergic psychosis. 
Positive effects (cannabis): Relaxation, increased appetite, feelings of happiness, 
sleepiness 
Problematic effects (cannabis): Nausea, hallucinations, anxiety, panic attacks, 
paranoia, psychological dependency, impaired judgement, reduced motivation, acute 
and chronic lung problems. Long term effects include reduced motivation and 
persistent cognitive impairment.  
Overdose risk: Small 
Withdrawal: Unlikely, although symptoms may include anorexia, disturbed sleep, 
irritability and moodiness.  
Alcohol 
Alcohol (ethanol) is one of the most commonly used and abused drugs. It is a 
depressant drug that slows down body reactions and general brain function. In 
Australia the 12 month prevalence of harmful use of alcohol is 3.0% while the 
prevalence of dependence is 3.5%. Men are twice as likely to suffer dependence 
compared with women. It is the secondary effects of alcohol that make it dangerous 
with motor vehicle accidents, alcohol-related violence (including domestic violence) 
and liver disease all major causes of morbidity and mortality. Alcohol is readily 
available and its consumption, even in excess, has become part of our culture. The 
depressive effects of alcohol makes it a significant risk factor in the development of 
mental health problems, particularly depression. 
Short term effects: Relaxation, reduced social inhibition, slurring of speech, reduced 
motor-coordination, reduced vision, reduced consciousness 
Long term effects: Liver disease, gastrointestinal disease, anemia, malnutrition 
(thiamine deficiency), central nervous system disturbances, depression  
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Overdose risk: Moderate, becomes particularly dangerous when used in conjunction 
with other substances (prescription benzodiazepines for example). 
Withdrawal: If dependence is established then withdrawal effects include nausea 
and vomiting, agitation, tremour, sweating, hallucinations, and seizures. It is 
potentially life threatening. 
Opioids 
Heroin, codeine, morphine, pethedine, diconal, palfium, methadone. 
Opioids are analgesic drugs derived from the opium poppy that have a wide range of 
effects on the mind and body. Opioids are generally taken to produce a sense of 
well-being and to reduce effects of stress and pain. Opioids are highly addictive and 
habit forming. Regular use quickly creates tolerance leading the user seeking 
increasingly larger doses of the drug to achieve the same effect. Accompanying 
tolerance is a powerful psychological craving for the drug and physical addiction that 
may produce strong withdrawal effects. It is these effects of opioids that create 
significant physical and mental health problems for the individual as they engage in 
behaviour that becomes increasingly focussed on obtaining and consuming the drug. 
Chemical contaminants may include talc, glucose, quinine and strychnine with 
associated harmful consequences. 
Short term negative effects: Depressed respiration, clouded mental functioning, 
nausea, vomiting, sweating, itchy skin and constipation. There is also a high risk of 
overdose that may lead to fatal respiratory depression.  
Long term effects: Poor health, lung complications, scarred or collapsed veins, 
abscesses, bacterial infections, blood borne viruses (eg. hepatitis, HIV).  
Associated problems:  Generally problems are associated with overdose and with 
injecting use. Hepatitis B and C, HIV, severe thrombophlebitis and intravascular 
sepsis, endocarditis, accidental arterial injection and peripheral ischaemia occur 
regularly in the injecting drug using community. 
Overdose risk:  Opioids may be lethal in overdose. Overdose results in 
respiratory and cardiovascular depression, loss of consciousness and death. 
Tolerance develops rapidly to opioids. Illicit drug availability varies considerably and 
hence purity of street available drugs vary, increasing the risk of accidental overdose. 
Withdrawal: In the dependent person withdrawal is uncomfortable. Features 
include sleeplessness, restlessness and agitation, abdominal and general muscular 
pains, diarrhoea and nausea, shivers and pilo-erection.  
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Stimulants 
Cocaine, amphetamine, methamphetamine, ecstasy (MDMA), methylphenidate, 
ephedrine, pseudoephedrine (Sudafed).  
Stimulants are recreational drugs that are purported to enhance sociability, 
confidence and alertness while reducing inhibition. The sensation of euphoria and 
well being that is associated with the use of stimulants becomes highly sought after 
but is usually only short lasting. The physiological effects of stimulants are well 
documented and include increased heart rate and energy level while reducing the 
influence of tiredness. The psychological effects of stimulants, particularly prolonged 
use, are not so well documented. There is some evidence that stimulants may have 
significantly negative effects on consciousness and mental state. Indeed it has been 
suggested that it may be difficult to distinguish primary psychotic and primary mood 
disorders from chronic stimulant use induced symptoms. 
Short  term effects: Periods of euphoria, increased sexual activity, paranoia, 
empathy, enhanced sociability, fear dissolution, hallucinations, appetite suppression, 
increased energy level, stamina and racing thoughts followed by periods of 
depression and low energy. 
Associated problems: Anxiety, depression, paranoia, tremor, mydriasis, 
tachycardia, diaphoresis, hypertension, hypothermia, risk of suicide, dehydration, 
acute renal failure, seizures, arrhythmias, hyponatremia, nausea, muscle cramping, 
jaw clenching, jitteriness. Injecting drug use associated with risks as stated above for 
opioids. 
Overdose risk: Low to medium for oral use, however there is a high risk of overdose 
associated with injecting use. 
Withdrawal: symptoms include depression, dysphoria, fatigue, exhaustion and 
somnolence, and loss of appetite lasting up to two weeks. Following prolonged use 
insomnia, intense dreaming and irritability may ensue and last several weeks to 
months. 
Benzodiazepines  
Flunitrazepam (rohypnol), lorazepam, diazepam, temazepam, clonazepam, 
oxazepam. 
Benzodiazepines are sedative drugs that may be prescribed to reduce anxiety, to 
encourage sleep or to act as a muscle relaxant. The non-prescribed use of these 
psychotherapeutic medications is frequent. The most likely to be abused are those 
that are short acting or rapidly absorbed, producing a more rapid feeling of 
intoxication. These prescribed medications have become the target of doctor 
shoppers and they are sold or exchanged on the street.  Benzodiazepines are often 
used in combination either with other benzodiazepines or with other illicit drugs eg. 
Flunitrazepam may be taken by heroin users to prolong the effect of a heroin 
injection and to reduce the effects of withdrawal. In non-poly drug users 
psychological addiction may occur when benzodiazepines are taken in an attempt to 
medicate (self-medicate) symptoms that are associated with an undiagnosed mental 
health problem.  
Short term effects: Euphoria, hallucinations, disinhibition, skeletal muscle 
relaxation, sedation, light and sound sensitivity, memory impairment. 
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Associated problems: Drowsiness, forgetfulness, confusion, depression, digestive 
problems, tachycardia, apnea, ataxia, hypotension, seizures, nausea. When injected 
intravenously vein damage is common. When injected arterially accidentally they can 
result in peripheral ischaemia an gangrene. 
Risk of overdose: Variable depending upon the strength of particular tablets. 
However, taken in large amounts and/or in-conjunction with other substances 
(usually alcohol) benzodiazepines there is a high risk of overdose, particularly in 
people with a high suicide risk. 
Withdrawal: There is an established withdrawal effect associated with use of 
benzodiazepines. Likelihood of withdrawal is higher for stronger, shorter acting types 
that are used for a long period of time. Withdrawal effects include anxiety, 
depression, problems sleeping, irritability, palpitations and sensory disturbances.  
Seizures can occur with sudden withdrawal from more than 50mg/day of diazepam.  
 
Tobacco 
While tobacco use is fairly common in the general adult population, it is particularly  
widespread in patients with psychosis (87% in one study) and probably accounts for 
a significant component of the increased morbidity and premature death seen in 
patients with chronic psychosis. 
The use of Bupoprion (Zyban) is relatively contraindicated in bipolar disorder as its 
antidepressant  effects may lead to hypomania.  
Tobacco may induce the metabolism of some of the anti-psychotics and hence 
lessen their side-effects.  Nicotine may lessen some side-effects of neuroleptic 
directly.  
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Depression and Substance Use 
Depression is a debilitating disorder that disrupts relationships and daily lives. It is 
common, affecting approximately 10 percent of the general population. It is twice as 
common in women as in men, although both sexes suffer its effects.  
Depression may be characterised by the presence of a majority of the following 
symptoms:  
• Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g. the person feels sad or empty or appears tearful). In 
children and adolescents, this may be characterised as an irritable mood. 
• Markedly diminished interest or pleasure in all, or almost all, activities most of 
the day, nearly every day.  
• Significant weight loss when not dieting or weight gain (a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every 
day. 
• Insomnia or hypersomnia nearly every day.  
• Psychomotor agitation or retardation nearly every day.  
• Fatigue or loss of energy nearly every day.  
• Feelings of worthlessness or excessive or inappropriate guilt nearly every day.  
• Diminished ability to think or concentrate, or indecisiveness, nearly every day.  
• Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide 
To be described as suffering a major depressive episode a person must either have 
a depressed mood or a loss of interest or pleasure in daily activities consistently for 
at least a 2 week period. This mood must represent a change from the person's 
normal mood. Social, occupational, educational or other important functioning must 
also be negatively impaired by the change in mood.  
Comorbidity  
People develop co-existing depression and substance use problems for a variety of 
reasons. The question about which came first is vexed but should not delay 
treatment of either disorder. Preferably the substance use should be ceased but this 
is not always possible. People self medicate with a variety of drugs to alleviate the 
symptoms of the depression. The effect that the drugs have depends on the drug 
itself, the particular individual’s response to the drug, the duration of the drug use and 
the particulars of the mental disorder, in this case depression. Long-term use of 
stimulants, such as amphetamines and MDMA have been identified as producing 
depletion of neurotransmitters, thus causing or aggravating depression. Alcohol 
dependence frequently causes depressive symptoms. However psychosocial effects 
such as stigma, poverty and isolation associated with drug use may also be highly 
relevant.  
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Major clinical issues with cannabis, hallucinogens and 
depression 
Effect of substance on mental disorder.  
• Some people may use cannabis to self manage their depressive 
symptoms.  
• However the sedative effect of cannabis may exacerbate depression.  
• Amotivational syndrome (associated with long term heavy usage) may 
simulate the cognitive and psychomotor features of depression.   
• Long-term heavy use also thought to cause a depression like 
syndrome. 
• Cannabis may mask appetite loss, thus concealing the extent of 
vegetative changes in more severe depression.  
Drug interaction with therapeutic agents.  
• Cannabis will augment the sedative effect of benzodiazepines and 
tricyclic antidepressants.  
• Cannabis has been reported to cause mania with fluoxetine. 
Confusion, depersonalisation, psychosis and hypomania have also 
been reported with concurrent use of cannabis and SSRIs.  
• LSD may induce a serotonin syndrome with SSRIs. 
Management approaches 
• Because of the sedative effect of cannabis patients should be advised 
to reduce or stop their use so that depressive symptoms can be better 
evaluated.  
• While adverse effects have been reported as above with concurrent 
use of SSRIs and cannabis, the risk is probably small. Patients should 
be counselled accordingly.  
• Patients should be counselled re the signs of serotonin syndrome if 
SSRIs are to be used while the patient is using cannabis. 
 Major Clinical issues with alcohol and depression 
Effect of substance on mental disorder.  
• Depression is a common feature of alcohol dependence. In many 
instances the depression will resolve if the alcohol is ceased.  
• In addition the depressant effect of alcohol will exacerbate a clinical 
depressive disorder. In fact chronic heavy use has been shown to 
induce a depression-like condition that is difficult to distinguish from 
major depressive disorder itself.  
• Similarly a depression like set of symptoms may emerge during or 
after alcohol withdrawal.  
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Drug interactions 
• Alcohol induced sedation will exacerbate the effects of 
benzodiazepines, tricyclic antidepressants, nefazodone and 
mirtazepine. Chronic alcohol use has a variable effect on the 
metabolism of some antidepressants. 
• There is limited experience with drug interactions with acamprosate. 
Does not interact with imipramine, diazepam or disulfiram.  
• Naltrexone will have a blocking effect on opiates used as analgesics.  
Management approaches 
• If a patient is clinically depressed and drinks harmful quantities of 
alcohol then they should be advised to stop drinking so that the 
symptoms can be evaluated in a drug-free setting.  
• In men this commonly results in a resolution of the depressive 
symptoms. 
• Women more commonly drink in response to a primary depression. 
Management therefore may involve the use of an anti-depressant as 
well as cessation of the alcohol.  
• If this is not possible then use of antidepressants is indicated (SSRIs 
are safer than  tricyclics in overdose with/without combination with 
alcohol). Response to antidepressants is less satisfactory in a heavy 
drinking situation.  
• Cognitive therapy may not be possible or beneficial with persons 
drinking heavily.   
• Acamprosate or naltrexone may be used to assist with abstinence 
supported by structured counselling.  
Major clinical issues with depression and opiate use 
Effect of opioids on mental disorder  
• Opioids’ depressive effects will exacerbate depressive disorders. 
Again the euphoric effects may assist with some of the more negative 
cognitive symptoms of depression. 
• Some depression resolves once patients are stabilised on methadone.  
Drug interactions 
• Opioids will exacerbate the effects of the sedative antidepressants, 
especially the tricyclics. 
• Fluoxetine, fluvoxamine, paroxetine and nefazodone potently inhibit 
some of the cytochrome systems in the liver; these enzyme systems 
metabolise several opioids including methadone. Fluvoxamine has 
been associated with methadone toxicity, and then when ceased, 
opioid withdrawal has developed.  
• Citalopram and sertraline are less likely to have this effect.  
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• Carbamazepine (used as a mood stabiliser) will induce the 
metabolism of methadone and reduce levels. Sodium valproate does 
not have this effect.  
Management approaches 
• Evaluation of depression difficult while the patient is using opioids 
heavily. Therefore initial cessation recommended.  
• Non sedating antidepressants (SSRIs, venlafaxine) preferable. Watch 
for interactions if using methadone or buprenorphine.  
• Overdose risk is greater with combined tricyclic and opiate use.  
• CBT difficult while using opioids but it provides additional benefit in 
combination with a methadone program.  
 Major clinical issues with depression and stimulant use 
Effect of substance on mental disorder. 
• Depression is a common feature of the cycle of dependence in 
stimulant users. 
• People with depression sometimes use stimulants to self-treat the lack 
of energy associated with the depression. However tolerance to this 
effect develops quite quickly. There is a risk that stimulants might 
provide the severely psycho-motor retarded depressed person with 
the ability to self harm. 
• Depression is exacerbated when stimulant effect wears off.  
• Stimulant effect on sleep may worsen sleep wake cycle disturbances 
associated with depression.  
• Depression is common in the months following cessation of 
stimulants.  
Interactions between stimulants and antidepressants 
• Irreversible monoamine oxidase inhibitors (tranylcypromine or 
phenelzine) should not be prescribed if stimulants are used.  
• Some stimulants inhibit the metabolism of tri- and tetra-cyclic 
antidepressants. If the clinician is aware of stimulant use then other 
anti-depressants are probable better choices.  
• Most anti-depressants, as well as cocaine both lower seizure 
thresholds. Increased seizures have been reported.  
• Serotonin syndrome may occur with cocaine or MDMA/ecstasy and 
SSRIs and patients should be warned about this. 
• MDMA metabolised through CYP 2D6. This is inhibited by fluoxetine, 
paroxetine and norfluoxetine. 
• Patients should be told about the signs of serotonin syndrome (see 
appendix 1). 
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Management approaches 
• The predictable depressive symptoms that occur when drug levels drop 
just exacerbate the depression. The person using stimulants and who is 
depressed should be encouraged to reduce and stop the stimulant use.  
• If the person is dependent then formal drug detoxification should be 
considered. There is little consistent evidence that antidepressants are 
beneficial in management of stimulant withdrawal per se but if there is 
established coexisting major depression and stimulant use then 
antidepressants should be used. Benzodiazepines or pericyazine can also 
be helpful in the short-term management of withdrawal. 
• Citalopram and sertraline have least cytochrome mediated drug 
interactions but all SSRIs are potential precipitators of serotonin 
syndrome in people using cocaine and MDMA. 
• If use is only occasional and dependence is not present is not present 
then treatment as for depression can be commenced.  
• If the depression persists despite adequate withdrawal from the stimulants 
then treat as for primary depression.  
• CBT is best used when the patient is not intoxicated and stimulant use is 
minimal. 
 Major clinical issues in depression and benzodiazepine use 
Effect of substance on mental disorder  
• Benzodiazepines can relieve some of the symptoms of depression 
such as insomnia and agitation. However their sedative and 
depressive actions exacerbate the more negative symptoms of 
depression such as lack of energy, negative cognitions and 
anhedonia.   
• Sleep quality is impaired by benzodiazepines with suppression of 
REM sleep.  
• Adverse reactions to the benzodiazepine. For example paradoxical 
reactions such as aggression. 
Drug interactions 
• Benzodiazepines will exacerbate the sedative effect of the tricyclic and 
other antidepressants 
• Disulfiram will increase the plasma concentrations of diazepam. 
• The addition of nefazodone, fluoxetine and fluvoxamine will increase 
the levels of alprazolam, midazolam and triazolam potentially to toxic 
levels.  
Management approaches 
• Benzodiazepines can be useful for short term management of acute 
agitation, anxiety, panic and insomnia associated with depression but 
tolerance develops within a few weeks. Therefore this use should be 
restricted to a few days. 
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• Their long term use exacerbates depressive symptoms so that 
cessation should be a long term goal.  
• In general short acting benzodiazepines should be replaced with long 
half-life benzodiazepines and dosages reduced steadily over w few 
weeks or months.  
• Anti-depressant medication (SSRIs or other non-sedating 
antidepressants) can be commenced with the patient still taking 
benzodiazepines.   
• Citalopram and sertraline are the least likely SSRIs to have 
cytochrome mediated drug interactions.  
• CBT will be more effective if there is minimal sedation and anxiolysis 
due to the benzodiazepine use. 
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Anxiety Disorders and Substance Use 
In contrast to fear, which is a response to a realistic immediate danger, anxiety is a 
fearful response occurring in the absence of a specific danger. According to the 
National Survey of Mental Health and Wellbeing anxiety disorders are the most 
common form of mental disorder in the population with a one-year prevalence of 
9.7%. Patients experiencing anxiety may present with complaints of excessive fear or 
worry, or repetitive, intrusive thoughts or actions including worry about the future, 
health or relationships. These people may find it hard to relax, concentrate and sleep 
with physical symptoms such as heart palpitations, tension and muscle pain, 
sweating, hyperventilation, dizziness, faintness, headaches, nausea, indigestion, 
bowel disturbance and loss of sexual pleasure. In anxiety disorders the symptoms 
associated with anxiety are accompanied by changes in thoughts, emotions and 
behaviour that substantially interfere with the person’s ability to love and work. 
In general anxiety disorder the person experiences constant worry about harm 
befalling themselves or loved ones, about financial disaster, their health, work or 
personal relationships. Diagnostic indicators include:   
• Excessive anxiety and worry more days than not for at least 6 months, 
about a number of events or activities.  
• Difficulty controlling this worry.  
• Restlessness or feeling keyed up or on edge  
• Being easily fatigued  
• Difficulty concentrating or mind going blank  
• Irritability  
• Muscle tension  
• Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep)  
• Clinically significant distress or impairment in social, occupational, or 
other important areas of functioning but not due to the physiological 
effects of a substance, a general medical condition, or another mental 
disorder. 
Anxiety Subtypes 
There are also a number of anxiety subtypes including: 
• Panic disorder, where a person suffers recurrent panic attacks that 
cause significant distress or disability. Panic attacks involve an abrupt 
onset of intense fear.  
• Obsessive-Compulsive disorder, where a person experiences 
constant unwanted thoughts and conducts elaborate rituals in an 
attempt to control or banish these.  
• Social Phobia, where a person experiences fear that others will judge 
everything they do in a negative way, particularly when in the 
presence of unfamiliar people or under specific scrutiny. 
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• Posttraumatic Stress Disorder, where a person experiences 
flashbacks, intrusive thoughts or nightmares for years following major 
traumas like assault, war, torture, rape, vehicle accidents, and fires. 
 Anxiety usually begins in early adulthood and is often, bit not always, triggered by a 
series of significant life events. It frequently occurs in-conjunction with other mental 
disorders, for example between 30 and 40 percent of people with panic disorder and 
obsessive-compulsive disorder also suffer depression. Anxiety disorders may are 
also often complicated by self-medication with alcohol and other substances. 
Similarly substance use may be complicated by the development of anxiety 
symptoms. At times, it can be hard to distinguish primary symptoms of anxiety from 
withdrawal symptoms in a person with dependence on alcohol or benzodiazepines.  
Comorbidity 
Anxiety is commonly seen in association with substance use, however the 
relationship between the two is complex. Anxiety is common in withdrawal from 
alcohol, benzodiazepines, and opioids and is also common during intoxication with 
stimulants, marijuana and hallucinogens. The failure to recognise and treat anxiety 
can lead to worsening of substance use and associated problems vice versa. 
Major clinical issues with anxiety disorders and 
cannabis/hallucinogens 
Effect of substance on mental disorder.  
• Cannabis and the other hallucinogens can induce anxiety in 
susceptible people. This occurs during intoxication and when high 
doses have been used, for some time afterwards when drug levels 
have dropped.  
• Some people use cannabis to help them cope with the symptoms of 
an anxiety disorder that is not being properly managed.  
Drug interaction with therapeutic agents.  
• Cannabis will augment the sedative effect of benzodiazepines and 
tricyclic antidepressants.  
• Cannabis has been reported to cause mania with fluoxetine. 
Confusion, depersonalisation, psychosis and hypomania have also 
been reported with concurrent use of cannabis and SSRIs.  
• LSD may induce a serotonin syndrome with SSRIs. 
Management approaches 
• Because of the anxiety provoking effect of cannabis in some patients, 
they should be advised to reduce or stop their use so that their anxiety 
symptoms can be better evaluated. In many cases this will result in an 
overall reduction in anxiety symptoms.  
• If the anxiety symptoms started after commencement of the cannabis 
or other hallucinogen then the anxiety is probably a secondary 
phenomenon and cessation is indicated. 
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• If the patient has been using cannabis or other hallucinogens to self 
medicate, then appropriate anxiety specific CBT or drug based 
treatment is obviously indicated.   
• While adverse effects have been reported as above with concurrent 
use of SSRIs and cannabis, the risk is probably small. Patients should 
be counselled accordingly.  
• Patients should be counselled re the signs of serotonin syndrome if 
SSRIs are to be used while the patient is using cannabis. 
Major clinical issues with alcohol and anxiety disorders 
Effect of substance on mental disorder 
Alcohol has long been used to self medicate for symptoms of anxiety 
disorders. The effect is sustained although tolerance occurs. When alcohol 




• Alcohol will enhance the sedation that occurs with tricyclic 
antidepressants, some of which are still used for severe anxiety 
disorders.  
• Nefazodone has caused liver toxicity so its use with people with 
established liver disease is best avoided.  
Management approaches 
• Regardless of aetiology and “what developed first” the combination of 
an anxiety disorder and alcohol use disorder is problematic as both 
exacerbate each other.  
• Early assessment and management of the anxiety disorder using a 
behavioural approach is indicated.  
• Assessment of the alcohol use is indicated at the same time together 
with detox if required.  
• Drug management of the anxiety disorder with SSRIs nefazodone or 
venlafaxine may be indicated if behavioural therapy is not possible or 
successful.  
• Specific anti-craving therapies such as naltrexone or acamprosate are 
worth considering in this group of people.  
 Major clinical issues anxiety disorders and opiate use 
Effect of substance on mental disorder  
Opioids can have a positive effect on some symptoms of anxiety through their 
soporific and sedative effects and euphoria. However withdrawal effects can 
exacerbate and be exacerbated by anxiety disorders.  
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Drug interactions 
• Benzodiazepines are often used in the management of anxiety despite 
problems with tolerance and dependence. 
• Benzodiazepines and opioids used together increase the risk of fatal 
opiate overdose. 
• Similarly the use of methadone and benzodiazepines increases the 
risk of sedation. 
• Fluoxetine, fluvoxamine, paroxetine and nefazodone potently inhibit 
some of the cytochrome systems in the liver; these enzyme systems 
metabolise several opioids including methodone and buprenorphine. 
Citalopram and sertraline have less risk of this effect.  
Management approaches 
• The rapidly fluctuating blood levels of heroin exacerbate anxiety 
disorders due to withdrawal effects when levels are low. Therefore 
patients should be encouraged to reduce their use and if possible 
cease. 
• Methadone or buprenorphine maintenance improves health status and 
should be encouraged/offered. 
• If medication is indicated for treatment of the anxiety disorder, then 
non sedating medication (SSRIs, venlafaxine) favoured. 
• If long term benzodiazepine use is indicated then this should involve 
the use of contracts, registration with the relevant local government 
health authority and the prescribing doctor should be identified as the 
sole prescriber through the Health Insurance Commission. (Australia)  
• Daily dispensing of benzodiazepines with methadone or 
buprenorphine should be considered.  
Major clinical issues anxiety disorders and stimulant use 
Effect of substance on mental disorder  
Stimulants generally make the symptoms of anxiety disorders worse. Chronic 
amphetamine, and cocaine use can precipitate anxiety states and panic 
attacks. High dose use can precipitate obsessive cognitions and compulsive 
behaviour.   
Drug interactions 
• Irreversible monoamine oxidase inhibitors (tranylcypramine or 
phenylzine) should not be prescribed if stimulants are used.  
• Some stimulants inhibit the metabolism of tri- and tetra-cyclic 
antidepressants. If the clinician is aware of stimulant use then other 
anti-depressants are probably better choices.  
• Serotonin syndrome may occur with cocaine, amphetamines or 
MDMA/ecstasy and SSRIs. 
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• Paroxetine, fluoxetine and norfluoxetine and nefazodone potently 
inhibit CYP 2D6 which metabolises cocaine and MDMA. This may 
result in elevated levels of these latter substances.  
Management approaches 
• Reduction or cessation of stimulants is a first step in management as 
this will help to clarify the situation regarding the relative effects of the 
stimulant vs the disorder in generating anxiety symptoms.  
• Benzodiazepines may be helpful in the management of acute 
withdrawal and emergent acute symptoms but dosages should be 
slowly reduced.  
• When benzodiazepine use is minimised or stopped behavioural 
therapy can be effective.  
• Cognitive therapy can be commenced prior to this provided the person 
is not acutely intoxicated with stimulants or with benzodiazepines.  
• If stimulants have been used to self assist with social phobia then low 
dose benzodiazepines can be used to assist engagement with group 
therapy.  
• SSRIs (accepting theoretical risks with stimulants causing serotonin 
syndrome)  can be very effective for a variety of anxiety disorders if 
CBT is not successful or appropriate. 
• Citalopram and sertraline have least cytochrome mediated drug 
interactions but all SSRIs are potential precipitators of serotonin 
syndrome in people using cocaine and MDMA.  
Major issues with benzodiazepines and anxiety disorders 
Effect of substance on mental disorder  
Benzodiazepines are very effective for treating the acute symptoms of 
anxiety. However tolerance and dependence develop within a short period of 
time. If short acting benzodiazepines are used (eg alprazolam, oxazepam, 
temazepam) rapidly fluctuating blood drug levels may exacerbate the 
symptoms of the anxiety disorder.  
Drug interactions 
• Benzodiazepines will exacerbate the sedative effect of the tricyclic and 
other antidepressants 
• Disulfiram will increase the plasma concentrations of diazepam. 
• The addition of nefazodone, fluoxetine and fluvoxamine will increase 
the levels of diazepam, alprazolam, midazolam and triazolam 
potentially to toxic levels.  
Management approaches 
• Benzodiazepines should be reduced or stopped. This can be done 
gradually over a few weeks or months with safety. There should be a 
management plan that is agreed to prospectively by the patient.  
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• The patient can sign an authority form to allow all prescribing 
information to be sent by the HIC to the chief prescribing doctor. 
• The assistance of the clinical pharmacist or family member can be 
invaluable in ensuring restricted daily dispensing.  
• Once benzodiazepine dosage is minimised the patient can engage in 
CBT. Behavioural therapy involving desensitisation will only be 
effective if the patient feels anxious during exposure. Therefore 
benzodiazepine dosage should be minimised. In general short acting 
benzodiazepines should be replaced with long half-life 
benzodiazepines and dosages reduced steadily over a few weeks or 
months.  
• Specific anti-anxiety medication such as SSRIs can be commenced 
with the patient still taking benzodiazepines.   
• Citalopram and sertraline are the least likely SSRIs to have 
cytochrome mediated drug interactions.  
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Psychosis (Schizophrenia and bipolar disorder) and 
Substance Use 
The person experiencing psychosis in the context of concurrent illicit drug use 
presents a problem that is challenging for the diagnostic and management skills of 
the clinician. 
The psychoses are characterized by a loss of connectedness with reality. A person 
may develop false ideas or beliefs about reality (delusions). These may be based on 
false perceptions of reality (hallucinations). There are also characteristic flaws in the 
ways that people think. These are termed thought disorder. Examples are tangential 
thinking, loose associations between words and thoughts, and incoherence. 
Psychoses can occur in response to physical conditions. Eg acute delirium with 
septicemia. Alternatively psychoses can be functional. There are two broad classes 
of functional psychotic disorders, schizophrenia and bipolar disorder. Generally 
schizophrenia is a chronic condition with exacerbations, but always with some 
background symptoms, while bipolar disorder is generally an intermittent condition 
with full recovery in between episodes. There is considerable overlap between the 
two conditions and “fluidity of diagnosis”. Schizophrenia itself has so called “negative 
symptoms” such as social withdrawal and lack of energy and motivation that are 
similar to those found in depression.  
While the clinician may realise that the psychosis could be drug-induced and is 
cautious in the prescription of neuroleptics or sedatives to control the symptoms, they 
may be under pressure to respond to the manifestation of bizarre or potentially 
destructive thinking or behaviour. On the other hand alterations to the way the person 
behaves and thinks may be subtle in their early stages when early intervention may 
be most appropriate.  
Comorbidity with psychosis 
It is important to differentiate between three different phenomena with regard to 
psychosis and substance use: 
• Firstly people can suffer from an acute psychotic episode in response to 
substance use, in particular cannabis and the stimulants. 
• Secondly these substances can precipitate a psychotic disorder in 
predisposed individuals. 
• Thirdly use of substances can exacerbate the symptoms in people with a 
chronic psychotic disorder. Use of these drugs will often exacerbate their 
condition and make rehabilitation much more difficult.  
 
People with psychosis tend to use a broad range of substances for a variety of 
reasons. However because of cost cannabis and alcohol are the most used drugs in 
this group of people.  
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Major clinical issues in the management of psychosis and 
cannabis/hallucinogens.  
Effect of substance on mental disorder  
As mentioned above cannabis and other hallucinogens certainly can 
precipitate acute psychotic episodes both in people with established psychotic 
disorders and in those who do not. Psychotic episodes tend to occur more 
frequently at high doses and in the person who is using them for the first time. 
Many people using these drugs realize early on that the drug makes them “a 
bit paranoid” and make the decision not to use them again.  
In some people regular cannabis use may augment metabolism of anti-
psychotic agents and lessen side-effects, thus re-inforcing the use of the 
cannabis. A similar interaction is thought to underlie the high rates of cigarette 
usage amongst people with psychotic disorders.  
Generally outcomes for people with schizophrenia using cannabis are not as 
good as for those who do not use cannabis.  
Drug interactions 
• Most of the active ingredients of cannabis are metabolised through the 
hepatic cytochrome system.  
• There is sparse evidence regarding drug interactions between 
cannabis and most drugs including the anti-psychotic agents both 
“typical” and “atypical”. 
• The sedative effect of cannabis will augment similar side-effects of the 
antipsychotics. 
• Cigarette smoking will induce the metabolism of the typical anti-
psychotics and reduce plasma levels. It is unclear whether chronic 
cannabis consumption does the same. 
Management approaches 
• As mentioned above it is important to distinguish between people with 
an acute psychotic episode caused by the drug use, a first episode of 
a psychotic disorder or an acute episode in someone with an 
established chronic psychotic disorder.  
• In an acute psychotic episode caused by a drug, cessation of the drug 
will often result in resolution of the episode. Sometimes the use of an 
anti-psychotic medication or benzodiazepines is indicated for the first 
few days.  
• In general people with psychotic disorders should be counselled 
against using cannabis. In theory people with a psychotic disorder 
should avoid cannabis. In practice there are some who use small 
amounts infrequently and in whom there is no ill effect. For most 
people with schizophrenia cannabis makes them worse. This needs to 
be explored with the patient. 
• Education about the possible effects of cannabis on schizophrenia 
should be provided in the context of motivational interviewing and a 
“stages of change” model.  
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• Anti-psychotic medications are generally required for the ealry 
management of drug induced psychosis.  
Major clinical issues with alcohol and psychosis 
Effect of substance on mental disorder  
• Long term effects on the course of schizophrenia unclear. However 
alcohol has the potential for making an already disordered lifestyle 
even more disordered.  
• Relapse rates are higher for those people with schizophrenia and 
harmful alcohol use.  
• Alcohol tends to make the negative symptoms of schizophrenia worse. 
It probably has little effect on the positive symptoms.  
Drug interactions 
• Alcohol will exacerbate the sedative effects of many of the anti-
psychotics and cause additional psychomotor incoordination.  
• Alcohol exacerbates the orthostatic hypotension problems associated 
with many of the anti-psychotics. 
• Naltrexone: unknown interactions with anti-psychotics 
• Disulfiram: no major interactions with anti-psychotics 
• Acamprosate: no known drug reactions with the antipsychotics 
Management approaches 
• As mentioned above alcohol is used because of its relative 
accessibility but is often not the preferred drug.  
• If there is obvious harmful consumption and dependence then 
abstinence would be the strategy of choice. Patients need to be 
counselled accordingly. 
• Detoxification needs to be supervised and psychiatric 
assistance/advice available should there be a flare up of psychotic 
symptoms. 
• In combination with specific psychotherapy some consideration should 
be given to the use of adjuvant drug therapies such as disulfiram, 
naltrexone and/or acamprosate.  
Major clinical issues with schizophrenia and opiate use 
Effect of substance on mental disorder  
• As mentioned above the effects of opioids tend to be sedative and do 
not assist with self-management of the negative symptoms of 
schizophrenia.  
• However the euphoric response from the opioids may alleviate the 
depression and isolation that is often associated with psychotic illness.  
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• Opioid use is associated with poorer outcomes for the psychotic 
disorder. 
Drug interactions 
• Opioids (including methadone and buprenorphine) have an additional 
sedative effect to that of the anti-psychotics. Care with driving and 
machinery. 
• No significant pharmacokinetic interactions between methadone or 
buprenorphine and anti-psychotics.  
• No interactions between naltrexone and antipsychotics. 
Management approaches 
• Concurrent opiate dependence and psychotic disorder often means 
high levels of dysfunction and harm minimisation approaches should 
be pursued.  
• Psychotherapy may be interfered with by active psychotic symptoms. 
• Methadone or buprenorphine maintenance should be encouraged as 
these will result in better adherence with anti-psychotic management.  
• Close liaison with dispensing pharmacist will assist with gaining a 
good picture of adherence to treatment, levels of self care and general 
stability. 
Major clinical issues with psychosis and stimulant use.  
Effect of substance on mental disorder  
• Stimulants certainly can precipitate acute psychotic episodes both in 
people with established psychotic disorders and in those who do not.  
• Psychotic episodes tend to occur more frequently at high doses and in the 
person who is using them for the first time.  
• Psychotic symptoms are very common in those with stimulant 
dependence. Many people using these drugs realize early on that the 
drug makes them “a bit paranoid” and make the decision not to use them 
again. 
• Generally outcomes for people with schizophrenia using stimulants are 
not as good as for those who do not use cannabis.  
• Occasional use of low dose stimulants is unlikely to induce an acute 
psychotic episode in most people.   
Drug interactions 
• Stimulants generally do not interfere with anti-psychotics.  
Management approaches 
• As mentioned above it is important to distinguish between people with an 
acute psychotic episode caused by the drug use, a first episode of a 
psychotic disorder or an acute episode in someone with an established 
chronic psychotic disorder.  
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• In an acute psychotic episode caused by a drug, cessation of the drug 
will often result in resolution of the episode. Sometimes the use of an 
anti-psychotic medication or benzodiazepines is indicated for the first 
few days.  
• Any use of stimulants in someone with a chronic psychotic disorder 
will probably exacerbate their symptoms. Patients should be 
counselled accordingly.  
• An acute psychotic episode induced by stimulants is initially difficult to 
distinguish from that associated with schizophrenia. 
• Drug induced psychotic reactions tend to settle more quickly (a few 
days) than those due to functional psychoses.  
• Follow up of psychotic episode is important to ensure that the patient 
has not developed an underlying functional psychotic disorder. 
Major clinical issues with benzodiazepine use and the 
psychoses. 
Effect of substance on mental disorder  
• Benzodiazepines can be used for the management of the acute 
agitation and anxiety associated with an acute psychotic state.  
• They are used by patients to self manage positive psychotic 
symptoms. 
• May exacerbate negative symptoms such as depression and 
psychomotor retardation as well as slowing of cognitions. 
 Drug Interactions 
• Benzodiazepines will increase the sedative effects of the 
antipsychotics. This is sometimes used to assist with management of 
acute episodes.  
• Benzodiazepines may induce delirium, severe sedation and 
respiratory collapse when used with clozapine. 
Management approaches 
• Benzodiazepines can be very useful for the acute management of 
psychotic episodes in conjunction with major tranquilizers. Eg 
lorazepam, clonazepam and diazepam. 
• In general patients function better off benzodiazepines as they may 
exacerbate some of the negative symptoms of schizophrenia.  
• If the patient is using these for management of positive symptoms 
consider changing anti-psychotic medication to better address these.  
• When withdrawing benzodiazepines do this slowly. May result in flare 
up of positive symptoms. Converting to an equivalent dose of a long-
acting benzodiazepine like diazepam will often make this easier.  
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Personality Disorders and Substance Use 
Personality traits are conspicuous features of personality and are not necessarily 
pathological, although certain styles of personality traits may cause interpersonal 
problems. The personality disorders are not regarded as illnesses and so treatment 
and recovery are not really relevant. However some dominant personality traits and 
personality disorders result in problematic habitual behaviours that can be modified 
or at least managed on a system level. 
Of all the different types of personality disorders the emotionally unstable personality 
disorder (including explosive personality disorder and borderline personality disorder) 
and the dissocial personality disorder come to the attention of health providers and 
authorities the most. The explosive PD and the dissocial PD tend to end up in the 
criminal justice system. They are the groups with the highest rates of comorbid drug 
use.  
Other personality disorders include paranoid, schizoid, schizotypal, histrionic, 
narcissistic, avoidant, dependent, obsessive-compulsive, passive-aggressive, and 
self-defeating. Rates of comorbid drug use are near average in these groups. 
Borderline personality disorder is characterized by a pervasive pattern of instability in 
interpersonal relationships, self-image, and affect, as well as marked impulsivity as 
follows: 
• frantic efforts to avoid real or imagined abandonment 
• Intense and unstable interpersonal relationships alternating between 
extremes of idealisation and devaluation. 
• Identity disturbances with markedly and persistently unstable self-
image or sense of self. 
• Impulsivity in at least two areas that are potentially self-damaging (eg. 
spending, sex, substance abuse, reckless driving and binge eating) 
• Recurrent suicidal behaviour, gestures or threats, or self-mutilating 
behaviour 
• affective instability due to a marked reactivity of mood (ie intense 
episodic dysphoria, irritability, or anxiety, usually lasting a few hours 
and only rarely more than a few days) 
• Chronic feelings of emptiness. 
• Inappropriate, intense anger or difficulty controlling anger 
• Transient, stress-related paranoid ideation or severe dissociative 
symptoms. 
Comorbidity with personality disorders 
People with unstable emotional traits frequently use drugs in a non-functional and 
destructive manner. As stated above drug use is most common in the person with 
dissocial PD or the emotionally unstable PD group. Drugs tend to be sought out and 
used early in an attempt to manage the interpersonal difficulties and stresses that 
develop because of their personality related problems.  It is generally thought that the 
PD predates and leads to the drug use and dependence but one must consider the 
complex interplay of the drug related lifestyle and its effects on the person over many 
years. The relationship between the personality disorders and drug use is complex. 
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• Drug use is generally counter productive and people should be 
counselled through their use and brought to realise the problems that 
the drug use produces for them given their particular personalities. 
• Limit setting and contracting is extremely important in this client group. 
• Early case management with other primary care providers (emergency 
department staff, locum service, after hours staff and even emergency 
services and mental health staff) is indicated. 
• Drug use should be contracted. If benzodiazepine dependence is a 
problem then some type of maintenance contract with a single 
prescriber and pharmacist is indicated. If opiate use is a problem then 
consideration should be given to opiate substitution programs such as 
methadone or buprenorphine. 
• Regular scheduled consultations with restricted access to emergency 
services/ last minute appointments. There needs to be a balance 
between dependency fostering and providing the support that is 
required.  
 Major issues with personality disorders and 
cannabis/hallucinogen use 
Effect of drug on disorder 
Cannabis may be used in the context of poly drug use in the person with 
dissocial PD. It may be used alone in many other types of PD, for its euphoric 
and sedative effects in an attempt to relieve distress. 
Drug interactions 
The drug-based management of personality related problems is controversial. 
A variety of medications have been tried for some types of behaviors rather 
than diagnoses per se. Aggression and impulsivity have been treated with 
carbamazepine, lithium, sodium valproate, and the SSRIs. Good quality data 
on efficacy is limited. 
• Drug interactions therefore are similar to those encountered in people 
with co-morbidity with depression and substance use, depending on 
the medications being used.  
• Cannabis has been reported to cause mania with fluoxetine. 
Confusion, depersonalisation, psychosis and hypomania have also 
been reported with concurrent use of cannabis and SSRIs.  
• LSD may induce a serotonin syndrome with SSRIs. 
Clinical Considerations 
• Advice regarding cannabis usage in these disorders depends on the 
degree of dysfunction associated with their use as well as the 
standard range of problems associated with using an illicit substance.  
• Overall approach depends on the persons insight and readiness for 
change.  
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Major issues with the personality disorders and alcohol use 
Effect of substance on mental disorder  
Alcohol tends to cause disinhibition and blur judgement and thinking and so is 
associated with more acting out in people with dissocial and emotionally 
unstable PDs. This leads to violence or self-harm attempts. The occurrence of 
problematic behaviours when intoxicated is often stark.  
Drug interactions 
The drug-based management of personality related problems is controversial. 
A variety of medications have been tried for some types of behaviors rather 
than diagnoses per se. Aggression and impulsivity have been treated with 
carbamazepine, lithium, sodium valproate, and the SSRIs. Good quality data 
on efficacy is limited. 
Drug interactions therefore are similar to those encountered in people with co-
morbidity with depression and substance use, depending on the medications 
being used.  
Management approaches 
• Because of the problems associated with alcohol use and impulse 
control the patient should be guided towards insight regarding this.  
• Depending on the amount of insight and readiness for change the 
patient should be assisted with reducing or stopping alcohol use. The 
use here of acamprosate or naltrexone should be considered. 
However disulfiram may be problematic as these patients may drink 
impulsively despite being warned of the risks. 
• Assistance with problem solving skills and with simple behavioural 
management of stress can be helpful. 
• Formal CBT is more difficult with these people due to limited capacity 
for insight.  
Major issues with opiate use in people with personality 
disorders.  
Effect of substance on mental disorder  
• Some people with personality disorders use opioids in the context of 
poly-substance abuse. 
• In others opioids are used alone to relieve some of the distress 
associated with their behavioural and interpersonal problems. 
• The chaotic lifestyle associated with opiate abuse certainly 
exacerbates problems for people with dissocial PD and emotionally 
unstable PD.  
Drug interactions 
The drug-based management of personality related problems is controversial. A 
variety of medications have been tried for some types of behaviors rather than 
diagnoses per se. Aggression and impulsivity have been treated with 
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carbamazepine, lithium, sodium valproate, and the SSRIs. Good quality data on 
efficacy is limited. 
Drug interactions therefore are similar to those encountered in people with co-
morbidity with depression and substance use, depending on the medications 
being used.  
Management approaches 
• People should be counselled according to the degree of problems 
associated with the drug use. 
• Standard motivational interviewing techniques are useful here.   
• If dependence is present then maintenance opiate substitution should 
be considered in an effort to re-instate some order in their lives.  
• Once stabilised then specific therapeutic interventions for problematic 
behaviours can be considered.  
Major issues with people with personality disorders and 
stimulant use 
Effect of substance on mental disorder  
• Use of stimulants may exacerbate the impulsivity of people with 
emotionally unstable PD or dissocial PD.  
• People with other types of PD may use stimulants to assist with 
symptom control or for recreation.  
Drug interactions 
The drug-based management of personality related problems is controversial. A 
variety of medications have been tried for some types of behaviors rather than 
diagnoses per se. Aggression and impulsivity have been treated with 
carbamazepine, lithium, sodium valproate, and the SSRIs. Good quality data on 
efficacy is limited. 
Drug interactions therefore are similar to those encountered in people with co-
morbidity with depression and substance use, depending on the medications 
being used.  
• Serotonin syndrome may occur with cocaine or MDMA/ecstasy and 
SSRIs and patients should be warned about this. 
• MDMA metabolised through CYP 2D6. This is inhibited by fluoxetine, 
paroxetine and norfluoxetine. 
• Patients should be told about the signs of serotonin syndrome. 
• Citalopram and sertraline have least cytochrome mediated drug 
interactions but all SSRIs are potential precipitators of serotonin 
syndrome in people using cocaine and MDMA. 
Management approaches 
• People should be led to some insight regarding the negative effect of 
the stimulants on their impulsive behaviour.  
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• Education on the adverse health effects of stimulants should be 
discussed. 
• Simple problem solving skills and behavioural strategies for managing 
stress can be useful. However if frequent stimulant use if a factor then 
success can be limited.  
• CBT is best used when the patient is not intoxicated and stimulant use 
is minimal. 
Major issues with personality disorder and benzodiazepine 
use 
Effect of substance on mental disorder  
Benzodiazepines have been associated with reduced impulse control, 
disinhibition and increased levels of violence, particularly with people with 
dissocial PD, explosive PD and emotionally unstable PD.  
The pattern of use is very important. Some people use benzodiazepines in an 
intermittent binge pattern resulting in intoxication and disinhibition.  
Consequently their use should be discouraged.  
Drug interactions 
The drug-based management of personality related problems is controversial. 
A variety of medications have been tried for some types of behaviors rather 
than diagnoses per se. Aggression and impulsivity have been treated with 
carbamazepine, lithium, sodium valproate, and the SSRIs. Good quality data 
on efficacy is limited. 
Drug interactions therefore are similar to those encountered in people with co-
morbidity with depression and substance use, given that the SSRIs and mood 
stabilisers have been used in this group of patients to assist with problematic 
violent and other extreme behaviours. 
The addition of nefazodone, fluoxetine and fluvoxamine will increase the 
levels of diazepam alprazolam, midazolam and triazolam potentially to toxic 
levels.  
Management approaches 
• As mentioned above benzodiazepines are used frequently by people 
with dissocial, emotionally unstable and explosive PDs. 
• They are thought to have a negative effect on many of the problematic 
behaviors associated with these disorders. 
• Patients should be counseled to reduce and stop these drugs. They 
are addictive and dependence is common.  
• If dependence is present then gradual reduction is indicated. Initial 
change to longer acting benzodiazepines for this withdrawal is 
preferable. 
• If this is unsuccessful then maintenance can have a role as part of a 
containment strategy. However it must be emphasised that there is 
evidence that even maintenance dosing of benzodiazepines may be 
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deleterious. If this approach is adopted then the relevant authorities 
should be notified in each state jurisdiction, the drug use contracted; 
there should be one dedicated prescriber and dispensing pharmacy.  
• Extreme caution should be exercised with maintenance doses above 
40mg diazepam daily. 
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Eating Disorders 
Eating disorders such as anorexia and bulimia nervosa are more common in women, 
but men sometimes develop these disorders too. 
Anorexia 
Anorexia is characterized by a significant weight loss resulting from excessive 
dieting.  
Most women and an increasing number of men are motivated by the strong desire to 
be thin and a fear of becoming obese. Anorexics consider themselves to be fat, no 
matter what their actual weight is. In their attempts to become thinner, the anorexic 
will avoid food and taking in calories at all costs, which can result in death. People 
with anorexia usually strive for perfection. They set very high standards for 
themselves and feel they always have to prove their competence. They usually 
always put the needs of others ahead of their own needs. A person with anorexia 
may also feel the only control they have in their lives is in the area of food and 
weight. If they can't control what is happening around them, they can control their 
weight. Each morning the number on the scale will determine whether or not they 
have succeeded or failed in their goal for thinness. They feel powerful and in control 
when they can make themselves lose weight. Sometimes focusing on calories and 
losing weight is their way of blocking out feelings and emotions. Anorexics usually 
have low self-esteem and sometimes feel they don't deserve to eat.  
Signs and Symptoms (unique to anorexia nervosa) 
• Noticeable weight loss  
• Excessive exercise  
• Fatigue & muscle weakness  
• Obsession with food, calories, recipes  
• Unusual eating habits (ie. cutting food into tiny pieces, picking at food)  
• Noticeable discomfort around food  
• Complaining of being "too fat", even when thin  
• Guilt or shame about eating  
• Depression, irritability, mood swings  
• Evidence of vomiting, laxative abuse, diet pills or diuretics to control 
weight  
• Wearing baggy clothes to hide weight loss (or gain)  
• Frequently checking weight  
• Fainting spells and dizziness  
• Difficulty eating in public  
• Feelings of self worth determined by what is or is not eaten  
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Bulimia 
Bulimia is characterised by a cycle of binge eating followed by purging to try and rid 
the body of unwanted calories. A binge is different for all individuals. For one person 
a binge may range from 1000 to 10000 calories, for another, one cookie may be 
considered a binge. Purging methods usually involve vomiting and laxative abuse. 
Other forms of purging can involve excessive exercise, fasting, use of diuretics, diet 
pills and enemas. 
Bulimia sufferers are usually people that do not feel secure about their own self 
worth. They usually strive for the approval of others. They tend to do whatever they 
can to please others, while hiding their own feelings. Food becomes their only source 
of comfort. Bulimia also serves as a function for blocking or letting out feelings. 
Unlike anorexics, people with bulimia do realize they have a problem and are more 
likely to seek help. 
Signs and Symptoms of Bulimia 
• Binge eating  
• Secretive eating  
• Bathroom visits after eating  
• Vomiting  
• Laxative, diet pill or diuretic abuse  
• Weight fluctuations (usually with 10-15 lb range)  
• Harsh exercise regimes  
• Fasting  
• Severe self-criticism  
• Self-worth determined by weight  
• Fear of not being able to stop eating voluntarily  
• Self-deprecating thoughts following eating  
• Avoidance of restaurants, planned meals or social events  
• Substance abuse  
Physical and Medical Complications of Eating Disorders 
A range of physical/medical complications can occur due to eating disorders, 
generally associated with the dangerous eating habits and compensatory activities of 
these disorders.  
• Fatigue and lack of energy  
• Irregular menstruation  
• Dizziness & Headaches  
• Dehydration & electrolyte imbalances 
• Constipation and diarrhoea  
• Shortness of breath & Chest pains  
Primary Mental Health Care Australian Resource Centre    June 2002 
 38 
• Irregular heartbeat  
• Depression  
• Hair loss  
• Stomach pain and bloating  
• Erosion of teeth enamel  
• Chronic sore throat  
• Kidney and liver damage  
• osteoporosis  
• Insomnia  
• Low blood pressure  
• Gastric dilation and rupture, peptic  
• ulcers and pancreatitis  
• Anemia  
• Cardiac arrest and death 
Comorbidity of eating disorders and substance use 
• People with bulimia have high rates of comorbid alcohol dependence. 
In fact rates are much higher than normal healthy controls and higher 
than people with anorexia nervosa.  
• Bulimic women with alcohol dependency have higher rates of self-
harm, higher rates of borderline personality disorders, and poorer 
outcomes than those without alcohol related problems. 
• Cocaine and stimulants may also be used to control appetite and 
dependence can develop. 
• The disruptive symptoms of eating disorders often interfere with 
therapy for substance use disorders. 
• Drug use may assist with weight control, may be part of a risk taking 
or self harm pattern of behaviour or part of impulsiveness and loss of 
control.  
Major clinical issues with comobrbidity of eating disorders 
and cannabis/hallucinogen use 
Effect of substance on mental disorder  
Cannabis is not often abused by people with eating disorders.  
In moderate dosages cannabis stimulates the appetite. This may give the 
false impression of recovery from anorexia.  
Drug interactions 
Drug therapy is generally not used for the eating disorders with the 
exception of the anti-depressants for co-occurring depression. 
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Management approaches 
• Management of the cannabis use should be determined by the level of 
problem associated with the use. 
• Chronic intoxication will interfere with behavioural and cognitive 
therapies for the eating disorder.  
Major clinical issues with the comorbidity of alcohol abuse 
and eating disorders 
Effect of substance on mental disorder  
• Alcohol abuse is common with people with bulimia. (probably 20-25% 
incidence) 
• High rates of self harm and poorer prognosis in people with both 
eating disorder and alcohol dependence. 
Drug interactions 
• As drugs are usually not used in the management of the eating 
disorders the scope for drug interactions is less. 
Management approaches 
• The alcohol dependence and the eating disorder need to be 
addressed in an integrated manner. 
• Assistance with stress management (structured problem solving, 
behavioural therapy, cognitive therapy) may assist both impulsive 
binge eating behaviour and impulsive drinking.  
Major issues with eating disorders and opiate use 
Effect of substance on mental disorder  
• People with eating disorders do not usually abuse opioids.  
Drug interactions 
• As drugs are usually not used in the management of the eating 
disorders the scope for drug interactions is less. 
Management approaches 
• Management of the opiate use will be directed by the level of 
problems associated with this use.  
• While such a combination is unusual, the general approach should be 
based on stages of change models, harm minimisation and 
opportunistic management of both conditions in an integrated manner. 
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 Major issues with eating disorders and stimulants 
Effect of substance on mental disorder  
People with eating disorders frequently use stimulants in an attempt to 
moderate appetite and assist with exercise bingeing.  
Drug interactions 
As drugs are usually not used in the management of the eating disorders 
the scope for drug interactions is less. 
Management approaches 
• When assessing people with eating disorders a detailed drug history 
should be elicited. This should include specific inquiry about alcohol, 
stimulants, as well as diuretics, laxatives and thyroxine.  
• The use of stimulants at any level should be discouraged due to the 
risk of dependence and toxicity.  
• Assistance with stress management may assist with impulsive use of 
stimulants and with bingeing behaviours. 
• Standard management of the eating disorders should be commenced 
if the patient is willing and engaged. The use of stimulants should be 
addressed as this standard management is commenced.  
Major clinical issues with eating disorders and 
benzodiazepines 
Effect of substance on mental disorder  
People with eating disorders do not often use benzodiazepines.  
Drug interactions 
As drugs are usually not used in the management of the eating disorders 
the scope for drug interactions is less. 
Management approaches 
• Benzodiazepine use should be discouraged. If some dependence has 
been established then graduated withdrawal through slow reduction of 
dosage should be negotiated.  
• Standard management of the eating disorders should commence if the 
patient is willing and engaged.  
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Somatoform disorders 
Somatic presentations of underlying mental disorder or distress are extremely 
common. Many of these presentations are easy to sort out for the clinician with the 
underlying stressor or disorder quickly coming to the fore and the patient quite willing 
to attribute the physical symptoms to the underlying problem.  
However within this broad phenomenon of somatic symptoms is a group of people for 
whom somatic presentations become a predominant and persistent feature of their 
illness behaviour1. There is a number of diagnostic subtypes.  
Non simulated disorders 
Where there is no insight into and even denial of the psychological nature of the 
problem three diagnoses are used:  
Somatization disorder.  
Occurs when a person has the following features 
• At least two years of multiple and varied presentations without 
physical diagnosis. 
• Persistent refusal to accept reassurance 
• Impairment of social functioning. 
Persistent Somatoform pain disorder 
“Chronic pain syndrome”  tend to have persistent pain that is out of proportion 
with the underlying organic problem and which is refractory to most 
biomedical treatments. There is symptom hypervigilance , idiosyncratic beliefs 
in various pharmacological regimes and treatments and a tendency to move 
from one medical practitioner to another in the search of a cure.  
Hypochondriacal disorder.  
Occurs where a person presents repeatedly with physical symptoms and 
refuses to accept reassurances despite thorough [and often repeated] 
examination and investigation. 
Simulated disorders 
Where there is awareness that the symptoms and perhaps signs are being simulated 
but no awareness of gain then factitious disorder is likely. Where there is 
consciousness of the simulation as well as the gain being sought then malingering is 
the correct conclusion. Finally there are the conversion disorders where the patient 
mimics neurological or other phenomena but this mimicry reflects the patients 
understanding of how the phenomena present. During the simulation the neurological 
structures said to be non-functional can clearly be made to function by the examining 
medical practitioner. 
                                                
1 Goldberg D, Benjamin S, Creed F Psychiatry in General Practice 1994 Routledge London 
pp 230-246 
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Comorbidity with the Somatoform disorders 
 With people with these groups of disorders there is obvious scope for inappropriate 
drug use and comorbidity as the medical practitioner attempts to deal with some of 
the symptomatology before the correct diagnosis is recognised.  The Somatoform 
disorders are best managed behaviourally and with cognitive therapy. However to 
engage in these some degree of insight is required. If this insight cannot be achieved 
then a health system based containment strategy is required.  
Probably the most common Somatoform disorder to end up with comorbidity with 
substance use problems is persistent Somatoform pain disorder. Because of delay 
with diagnosis people with this disorder may well end up having opioids, 
benzodiazepines and other psychotropic drugs prescribed and dependence may 
occur in its own right. 
Somatoform disorders and cannabis/hallucinogens 
Effect of the cannabis/hallucinogen use on the disorder 
• These may have an effect on somatic symptoms in terms of making 
them more accentuated. 
• Some people with persistent Somatoform pain disorder use cannabis 
to assist with pain relief or with nausea associated with opiate use. 
Cannabis has no analgesic properties and its role in modulating pain 
and other symptoms is still being investigated.  
Drug interactions 
Drug management is not recommended in most Somatoform disorders. 
However many people with persistent Somatoform pain disorder are on 
opioids so there is a potential for increased sedation and psychomotor 
problems with cannabis  
Clinical considerations 
Approach depends on the nature of the drug use, what other drugs the 
person is taking and what problems there are associated with the drug use.  
If use is frequent an intoxication regular then this may interfere with cognitive 
behavioural therapy. Use at this level should be discouraged.  
Somatoform disorders and alcohol use  
Effect of alcohol on the disorder 
People with chronic Somatoform pain disorder may use alcohol to reduce 
pain symptoms. However it is not an analgesic and may interfere with the 
person’s ability to use cognitive strategies to manage their behaviour and 
their symptoms.  
Alcohol use and intermittent withdrawal may result in exacerbation of a variety 
of physical symptoms particularly associated with anxiety.  Depending on the 
nature of the Somatoform disorder this may be an issue. 
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Drug interactions 
Drug management is not recommended in most Somatoform disorders. 
However many people with persistent Somatoform pain disorder are 
prescribed opioids or tricyclics so there is a potential for increased sedation 
and psychomotor problems with alcohol at any level.  
There is no major interaction between disulfiram or acamprosate with the 
opioids if these are being used. Naltrexone will obviously interfere with opioid 
management.  
Clinical considerations 
If alcohol consumption is hazardous or harmful then the person should be 
counselled accordingly.  
Alcohol use that results in intoxication will interfere with CBT and will interfere 
with any structured problem solving or motivational therapy.  
Look for links between the patient’s symptomatology and alcohol use so that 
insight can be raised.  
Somatoform disorders and opioids 
Effect of opioids on the disorder 
• People with chronic Somatoform pain disorder frequently use opioids. 
These may be helpful in the management of organic aspects of the 
pain but because of the chronic nature of the pain and hence the 
opiate use, dependence is common.  
• In  some instances the actual prescription of the opiate is seen as a 
legitimization of the pain and an acknowledgement of its physical 
source. 
Drug interactions 
• Several analgesics and pain modulators cause sedation and the 
addition of an opiate will exacerbate this.  
• This is a concern with the use of benzodiazepines as well.  
Clinical approaches 
• If opioids are to be used then the advice of a specialist pain clinic is 
advisable. This type of clinic will provide a multi-disciplinary approach 
to the management of the patient’s pain that is not possible in general 
practice.  
• If opiate dependence is identified then this needs to be discussed with 
the patient and their readiness for change identified.  
• Change to a long acting opiate is preferable. 
• Use of methadone as part in a formalised program is also possible, as 
this will allow probable control of the pain and the drug seeking 
lifestyle.  
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Somatoform disorders and stimulants 
Effect of the stimulant on the disorder 
Stimulants may cause a variety of sympathetic nervous system related 
symptoms that may become clinical presentations. However these are 
generally short lived and drug level related.  
Stimulant use may contribute to the anxiety associated with some of the 
Somatoform disorders and resultant impulsively may result in presentation to 
the health practitioner at a lower threshold than usual.  
Drug interactions 
Potential interactions between stimulants and SSRIs. These latter may be 
being used for secondary depression but they should not be used as pain 
moderators as there is little evidence to support their use. (in contrast with 
tricyclic antidepressants)  
No particular interactions between stimulants and opioids and tricyclics.  
Major clinical considerations 
Depends on the nature of the stimulant use. The clinician needs to explore 
the reasons for the drug use and the possible negative effect on the person’s 
health and the Somatoform disorder. As discussed above stimulant use may 
contribute to symptoms and frequent presentations.  
If the use is harmful then the patient needs to be guided towards that 
realisation and readiness for change determined.  
Somatoform disorders and benzodiazepine use. 
Effect of benzodiazepines on the Somatoform disorder 
• People with Somatoform disorders often use benzodiazepines to 
alleviate anxiety symptoms or to moderate pain. Dependence is 
frequent. 
• Especially with short acting benzodiazepines fluctuating levels may 
result in exacerbation of the disorder, with lowered thresholds for 
presenting to the health system and withdrawal symptoms or 
“breakthrough anxiety”.  
Drug interactions 
Care with other potentially sedating drugs the person may be using (either 
prescribed or non prescribed) 
Major clinical considerations 
• Benzodiazepine use is common and dependence frequent. In general 
use should be discouraged due to dependence potential and 
psychomotor effects. 
• Withdrawal or dose reduction should be negotiated. 
• Change to a longer acting benzodiazepine is preferable both if they 
are being maintained or for dosage reduction.  
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• If the person is ready for change and willing to engage in CBT 
specifically for their Somatoform disorder then minimisation of 
benzodiazepine dosage is required so that the CBT is not interfered 
with.  
• If maintenance use of benzodiazepines is anticipated then this should 
be subject to a contract with the patient. Authorities should be 
advised. Advice from a psychiatrist should be sought.  
• Benzodiazepines are frequently prescribed to induce “muscle 
relaxation”. In reality very large (near anaesthetic doses) doses are 
required for this and benzodiazepines are not recommended for the 
relief of acute back pain.  
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Appendix 1 Serotonin syndrome 
 
Some medication combinations can cause the development of a 
condition called serotonin syndrome, due to too much serotonin 
being released into the nervous system and the rest of the body. 
The syndrome is potentially fatal. 
 
Common features are as follows: 
 
• Severe restlessness 
• Over-excitability and hyperactivity (hypomania) 
• Sweating and shivering 
• Diarrhoea 
• Fever 
• Lack of coordination 
• Confusion and altered consciousness 
• Tremour 
• Jerking limb movements (termed myoclonus) 
 
It is important to let your doctor know or attend an emergency 
department should you develop these symptoms. 
 
The syndrome can be treated with withdrawal of the medications 
that caused it in the first place. Sedative medications such as 
diazepam or lorazepam are sometimes needed. If more severe 
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